ImmunityBio, Inc. IBRX Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash

Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash at other companies

Summit TherapeuticsSMMT

——

Other financials

Income statement

See full

Revenue$44.2M+168%

Gross profit$44.0M+167%

Operating income-$69.8M-8.3%

Net income-$632.8M-388%

EPS (diluted)-$0.62-313%

Balance sheet

See full

Cash & equivalents$205.2M+238%

Total debt$445.4M+32.2%

Total equity-$870.0M-47.1%

Total assets$646.6M+113%

Cash flow

See full

Operating cash flow-$75.4M+12.3%

CapEx$1.8M+58.4%

Free cash flow-$77.1M+11.4%

Valuation

See full

Market cap$7.71B+208%

Enterprise value$7.95B+187%

P/S54.7×-25.4×

Profitability

See full

Gross margin99.3%-0.5pp

Operating margin-185.4%-83.3pp

Net margin-606.2%-212pp

FCF margin-212%-95.8pp

Returns & leverage

See full

Return on equity-119.3%—

Debt / equity0.1×—

Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s effect of currency exchange rate changes on cash, cash equivalents, and restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ImmunityBio, Inc.'s effect of currency exchange rate changes on cash, cash equivalents, and restricted cash?: ImmunityBio, Inc. (IBRX) reported effect of currency exchange rate changes on cash, cash equivalents, and restricted cash of $122K in Q1 2026.
How has ImmunityBio, Inc.'s effect of currency exchange rate changes on cash, cash equivalents, and restricted cash changed year-over-year?: ImmunityBio, Inc.'s effect of currency exchange rate changes on cash, cash equivalents, and restricted cash increased by 1320.0% year-over-year, from -$10K to $122K.